Why genetics companies struggle to move ML models into production
There are multiple very interesting areas in which biotech, and genetics, in particular, continue to evolve in order to provide help to patients, examples varying from drug discovery to early disease (or even just predisposition for them) identification. Nowadays, machine learning and artificial intelligence are often utilized in order to attempt to solve such problems – but those are very challenging, and companies face unique obstacles related to the field itself as well when working on such solutions. These hurdles are mostly attributed to the large volume of data involved as well as the complexities of ML development, which ultimately cause organizations to often struggle to move their ML models into production due to the intricacies of data management, model deployment, and scalability.




